CIDP Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Video
• Funding
• Clinical Trials
• Forums

A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)
Condition:   Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Interventions:   Biological: efgartigimod PH20 SC in stage B;   Other: placebo in stage B Sponsor:   argenx BVBA Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 24, 2020 Category: Research Source Type: clinical trials